Avidicure B.V.
Monday, June 03, 2024
Oncology
Company Presentation Theater 4
Avidicure develops AVC-Boosters for cancer immunotherapy. AVC-Boosters are supercharged antibodies that boost the number and function of NK cells at the tumor, cause activation of the full immune system and provide broad TME-resistant anti-tumor responses.
Company Website:
http://www.avidicure.com
Lead Product in Development:
AVC boosters
Company HQ City
Naarden
Company HQ State
N-Holland
Company HQ Country
Netherlands
CEO/Top Company Official
Arthur Lahr CEO
Development Phase of Primary Product
Discovery
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())